Moleculin up 19% premarket on encouraging annamycin data

|About: Moleculin Biotech, Inc. (MBRX)|By:, SA News Editor

Moleculin Biotech (NASDAQ:MBRX) announces that its ongoing sponsored research at The University of Texas MD Anderson Cancer Center has now demonstrated that Annamycin is able to significantly improve survival in an aggressive form of triple negative breast cancer metastasized to the lungs in animal models.

Shares are up 19% premarket.

Subscribe for full text news in your inbox